MA07.04 Amivantamab and Lazertinib in Combination with Platinum-Based Chemotherapy in Relapsed/Refractory EGFR-mutant NSCLC
M.E. Marmarelis, B.C. Cho, M. Thayu, S. Waqar, J.M. Bauml, Alexander I. Spira(Virginia Cancer Specialists), R.E. Knoblauch, S.-H. Lee(Samsung Medical Center), S.-H.I. Ou(Chongqing Medical and Pharmaceutical College), S. Li
Cited by 4
Related Papers
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
|Journal of Clinical Oncology|2018|3.7k
Sotorasib for Lung Cancers with <i>KRAS</i> p.G12C Mutation
|New England Journal of Medicine|2021|1.8k
Amivantamab plus Lazertinib in Previously Untreated <i>EGFR</i> -Mutated Advanced NSCLC
|New England Journal of Medicine|2024|369